RE:RE:RE:RE:RE:RE:REMINDER: BIO-Europe Spring 2014...1. It's on the Toronto exchange versus the NASDAQ (TSX doesn't get much respect). Institutional buyers like a $10 plus stock (I always thought it was $5). 2. It's still a failed technology ( he says you can't sell a drug that just works for a prefixed group..like just Crestor). 3. You can't keep doing trials to a group that you know it will work with. 5) regarding Zenitb it would light years of trials to get FDA approval on DNA type munipulations. 6) most important..DM is looked upon as a "trickster" in the space.
not my comments...don't shoot the messenger but recommendations he's given me over the past few years, as I see him one month out of the year plus extensive emails, have made me a bundle on other biotechs (don't ask what they are I'm not in the space of recommending or sharing). ..RVX was/is enought for me in this startup penny stock space. Will love to get out before I die..LOL! He thinks it will ultimate go bust!